PL2259800T3 - Zastosowanie 5-(2,6-dimorfolin-4-ylopirymidyn-4-ylo)-4-trifluorometylopirydyn-2-yloaminy do leczenia niedrobnokomórkowego raka płuca wykazującego nabytą oporność wobec modulatorów receptora dla naskórkowego czynnika wzrostu (EGFR) - Google Patents

Zastosowanie 5-(2,6-dimorfolin-4-ylopirymidyn-4-ylo)-4-trifluorometylopirydyn-2-yloaminy do leczenia niedrobnokomórkowego raka płuca wykazującego nabytą oporność wobec modulatorów receptora dla naskórkowego czynnika wzrostu (EGFR)

Info

Publication number
PL2259800T3
PL2259800T3 PL09716778T PL09716778T PL2259800T3 PL 2259800 T3 PL2259800 T3 PL 2259800T3 PL 09716778 T PL09716778 T PL 09716778T PL 09716778 T PL09716778 T PL 09716778T PL 2259800 T3 PL2259800 T3 PL 2259800T3
Authority
PL
Poland
Prior art keywords
ylamine
morpholin
egfr
pyrimidin
pyridin
Prior art date
Application number
PL09716778T
Other languages
English (en)
Inventor
Carlos Garcia-Echeverria
Sauveur-Michel Maira
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2259800T3 publication Critical patent/PL2259800T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PL09716778T 2008-03-05 2009-03-04 Zastosowanie 5-(2,6-dimorfolin-4-ylopirymidyn-4-ylo)-4-trifluorometylopirydyn-2-yloaminy do leczenia niedrobnokomórkowego raka płuca wykazującego nabytą oporność wobec modulatorów receptora dla naskórkowego czynnika wzrostu (EGFR) PL2259800T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08152326 2008-03-05
EP09716778.7A EP2259800B1 (en) 2008-03-05 2009-03-04 Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.
PCT/EP2009/052564 WO2009109605A1 (en) 2008-03-05 2009-03-04 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Publications (1)

Publication Number Publication Date
PL2259800T3 true PL2259800T3 (pl) 2014-09-30

Family

ID=39343633

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09716778T PL2259800T3 (pl) 2008-03-05 2009-03-04 Zastosowanie 5-(2,6-dimorfolin-4-ylopirymidyn-4-ylo)-4-trifluorometylopirydyn-2-yloaminy do leczenia niedrobnokomórkowego raka płuca wykazującego nabytą oporność wobec modulatorów receptora dla naskórkowego czynnika wzrostu (EGFR)

Country Status (14)

Country Link
US (2) US20110033453A1 (pl)
EP (3) EP2599499A1 (pl)
JP (2) JP2011513364A (pl)
KR (1) KR20100131446A (pl)
CN (2) CN105343102A (pl)
AU (1) AU2009221164B2 (pl)
BR (1) BRPI0908049A2 (pl)
CA (1) CA2716518A1 (pl)
ES (1) ES2471452T3 (pl)
MX (1) MX2010009743A (pl)
PL (1) PL2259800T3 (pl)
PT (1) PT2259800E (pl)
RU (2) RU2496500C2 (pl)
WO (1) WO2009109605A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100039354A (ko) * 2007-07-24 2010-04-15 노파르티스 아게 Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 이미다조퀴놀린의 용도
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
DK2300013T3 (en) 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
AU2011315831B2 (en) * 2010-10-14 2015-01-22 Takeda Pharmaceutical Company Limited Methods for inhibiting cell proliferation in EGFR-driven cancers
CA2832504C (en) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
PE20141581A1 (es) 2011-09-27 2014-11-14 Novartis Ag 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
CN102397544A (zh) * 2011-11-25 2012-04-04 百泰生物药业有限公司 一种单克隆抗体用于治疗非小细胞肺癌的用途
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
MX369518B (es) * 2012-08-16 2019-11-11 Novartis Ag Combinacion de inhibidor de p13k e inhibidor de c-met.
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
ES2665619T3 (es) 2013-03-14 2018-04-26 Novartis Ag 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
ES2784900T3 (es) * 2014-12-12 2020-10-01 Massachusetts Gen Hospital Tratamiento de metástasis cerebrales del cáncer de mama
CN111529530B (zh) * 2020-04-02 2021-06-04 中山大学 一种吡啶并咪唑类STAT3抑制剂在制备延缓或逆转TKIs获得性耐药药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
RU2294761C2 (ru) * 1999-05-14 2007-03-10 Имклон Систимс Инкопэритид Лечение резистентных опухолей человека антагонистами рецепторов фактора роста эпидермиса
ES2412273T3 (es) * 2002-11-21 2013-07-10 Novartis Ag Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20100039354A (ko) * 2007-07-24 2010-04-15 노파르티스 아게 Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 이미다조퀴놀린의 용도

Also Published As

Publication number Publication date
PT2259800E (pt) 2014-08-06
KR20100131446A (ko) 2010-12-15
BRPI0908049A2 (pt) 2015-08-11
RU2496500C2 (ru) 2013-10-27
US20110033453A1 (en) 2011-02-10
JP2014040446A (ja) 2014-03-06
CA2716518A1 (en) 2009-09-11
CN101959533A (zh) 2011-01-26
US20140161722A1 (en) 2014-06-12
EP2599499A1 (en) 2013-06-05
AU2009221164B2 (en) 2012-07-26
RU2013132018A (ru) 2015-01-20
JP2011513364A (ja) 2011-04-28
WO2009109605A1 (en) 2009-09-11
JP5778735B2 (ja) 2015-09-16
EP2591805A1 (en) 2013-05-15
ES2471452T3 (es) 2014-06-26
EP2259800A1 (en) 2010-12-15
EP2259800B1 (en) 2014-05-07
RU2010140435A (ru) 2012-04-10
CN105343102A (zh) 2016-02-24
MX2010009743A (es) 2010-09-28
AU2009221164A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
PT2259800E (pt) Utililização de 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4- trifluorometil-piridin-2-ilamina para o tratamento de carcinoma pulmonar de não pequenas células com resistência adquirida aos moduladores do receptor de factor de crescimento epidérmico (egfr)
EP2253625A4 (en) PYRIDAZINONES, PREPARATION AND USE THEREOF
SI2376537T1 (sl) Humana protitelesa zoper humani faktor tkiva
IL211400A0 (en) Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
WO2009046141A3 (en) Antisense modulation of fibroblast growth factor receptor 4 expression
AP00409S1 (en) Multidose Inhaler.
AP2010005379A0 (en) Anti-TRKA antibodies and derivatives.
IL202674A0 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
HK1151791A1 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
SI2598503T1 (sl) Derivati cis-tetrahidro-spiro(cikloheksan-1,1'-pirido(3,4-b)indol)-4-amina
ZA201100210B (en) Pyridino-pyridinone derivatives,preparation thereof,and therapeutic use thereof
PL2155824T3 (pl) Preparat pigmentowy, sposób jego wytwarzania i jego zastosowanie
EP2274437A4 (en) COMPOSITIONS AND METHODS FOR DETECTION OF EGFR MUTATIONS IN CASES OF CANCER
PL2401263T3 (pl) Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu
ZA201008657B (en) 4,5-dihydro-oxazol-2-yl derivatives
WO2009150255A3 (en) Markers for predicting response and survival in anti-egfr treated patients
EP2354136A4 (en) NEW DOPAMINE D3 RECEPTOR LIGANDS, THEIR PREPARATION AND USE
IL211210A0 (en) Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof
PL2370070T3 (pl) Pimobendan do zastosowania w leczeniu kardiomiopatii przerostowej u kotów
IL207629A0 (en) Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof
EP2155705A4 (en) COMPOSITIONS FOR REGULATING OR MODULATING QUORUM DETECTION IN BACTERIA, METHODS OF USING THE SAME, AND METHODS OF REGULATING AND MODULATING QUORUM DETECTION IN BACTERIUM
IL207722A (en) Pyridopyrazinone Derivatives as Insulators, Methods of Preparation and Use for Diabetes
FR2933609B1 (fr) Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
HK1218857A1 (zh) ' - ' - '- 用於腎臟細胞癌的治療的 '， '-四羥基- '-聯吡啶- '-二氧化物
ZA201005306B (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use